XLONSBTX
Market cap49mUSD
Dec 24, Last price
17.25GBP
1D
-1.43%
1Q
62.28%
IPO
18.26%
Name
SkinBioTherapeutics PLC
Chart & Performance
P/E
—
P/S
3,260.22
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.65%
Rev. gr., 5y
%
Revenues
1m
+815.26%
Net income
-3m
L+1.44%
CFO
-3m
L+3.07%
Earnings
Mar 20, 2025
Profile
SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.
IPO date
Apr 05, 2017
Employees
12
Domiciled in
GB
Incorporated in
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | 1,209 815.26% | 132 76.64% | 75 | ||||||
Cost of revenue | 1,330 | 1,140 | 993 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (121) | (1,008) | (918) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (73) | (173) | (200) | ||||||
Tax Rate | |||||||||
NOPAT | (48) | (835) | (718) | ||||||
Net income | (2,876) 1.44% | (2,835) 1.52% | (2,793) 94.88% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 3,120 | 2,353 | |||||||
BB yield | -20.16% | -11.43% | |||||||
| Debt | |||||||||
Debt current | 779 | 31 | 27 | ||||||
Long-term debt | 119 | 139 | 201 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 250 | (1) | |||||||
Net debt | 97 | (1,142) | (1,576) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (2,726) | (2,645) | (2,673) | ||||||
CAPEX | (28) | (165) | (97) | ||||||
Cash from investing activities | (2,297) | (165) | (97) | ||||||
Cash from financing activities | 4,512 | 2,317 | (35) | ||||||
FCF | 9 | (835) | (675) | ||||||
| Balance | |||||||||
Cash | 801 | 1,312 | 1,805 | ||||||
Long term investments | |||||||||
Excess cash | 740 | 1,305 | 1,801 | ||||||
Stockholders' equity | (11,976) | (8,953) | (6,283) | ||||||
Invested Capital | 16,015 | 10,985 | 8,854 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 176,883 | 164,713 | 156,780 | ||||||
Price | 0.09 -30.00% | 0.13 -38.27% | 0.20 -68.11% | ||||||
Market cap | 15,477 -24.83% | 20,589 -35.15% | 31,748 -65.92% | ||||||
EV | 15,574 | 19,448 | 30,172 | ||||||
EBITDA | 55 | (964) | (888) | ||||||
EV/EBITDA | 282.76 | ||||||||
Interest | 51 | 9 | 10 | ||||||
Interest/NOPBT | |||||||||